A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
about
sameAs
Overview of the biology of type I interferonsDifferent strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathwayMultiple sclerosis-a quiet revolutionBiomarkers of therapeutic response in multiple sclerosis: current statusPersonalized medicine in multiple sclerosis: hope or reality?Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple SclerosisSolving the puzzle of autoimmunity: critical questionsType I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosisConstitutive type I interferon modulates homeostatic balance through tonic signalingAn RNA profile identifies two subsets of multiple sclerosis patients differing in disease activityAberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body EcologyFeasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosisGene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosisEndogenous and recombinant type I interferons and disease activity in multiple sclerosisReassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosisExcessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosisEndothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-β autocrine signaling to promote monocyte recruitment.A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes.How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.Interferon-β exacerbates Th17-mediated inflammatory disease.Molecular mechanism underlying the impact of vitamin D on disease activity of MS.Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients.Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-betaTransient oscillatory dynamics of interferon beta signaling in macrophagesInterleukin 17F level and interferon β response in patients with multiple sclerosis.Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy.Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controlsTranscriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.Janus-like effects of type I interferon in autoimmune diseases.Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.An interferon response gene expression signature is activated in a subset of medulloblastomasMyxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.
P2860
Q21195364-6DED0ABC-B655-4629-99B3-4CE8FCDC2F01Q24611933-7AD6EA74-8308-4E88-8EB8-A971D95816C2Q26826930-45BC9AB3-4DCD-4A88-8F2D-753040D650BFQ27012726-D949D6E5-6047-4468-9161-24916D75C218Q27025933-C141A77B-FA14-4531-AB1C-2F59E960CAA3Q28080754-9EF15E47-ABEC-45BE-A946-6E07F50495B7Q28084677-6DC4DFF4-93D8-4F18-9DA3-CB7857AA76A2Q28251763-57F1A845-4535-4BFC-A6EB-4A197FF510A6Q28260631-7BEB57E9-0E9D-4A14-8776-C18F69FF58A0Q28275948-029DD09A-6D6E-4DF0-8129-FE7677D0B38CQ28299160-F76818EA-2B0E-4CC9-BDE9-9954D863D433Q28535303-F00FE6B6-B2C8-4AA6-993A-246B375DF024Q28540781-D19F7CB6-40EA-46B6-99CF-8FAA16029223Q28728759-19F2E310-3AAC-4B7C-BA49-F7317C59F197Q28740839-80A11EAD-A348-458B-8125-99D6D8CEBCF2Q28744592-48E46F4A-9D1B-402E-BD35-F1000DE1FF0CQ30543966-075D2C11-9D3D-47BC-B539-FFBCB96E60FAQ33789317-0938AD89-A00C-4D5A-AB54-F87DA13350A4Q33988240-7CFA5BD9-6242-4022-A7C1-A458D4C7FC21Q34008878-64F6D624-0932-4573-9001-6337832843C2Q34181184-60AB64DF-C700-4A3E-A90A-92595C257770Q34268651-C6A25B1C-9066-4AEE-8622-AD1F61BD02D1Q34513928-AB5303EB-CB6C-415C-AB95-040B64E3646EQ34700070-E5FFE5DB-0D11-4B00-8051-D13AF6492B94Q34803273-3B878BAB-CCCC-41C4-A9F0-9AA779A86A65Q34915610-B40BFF26-AB4A-44B4-AE3E-09C09F2EBBAFQ35040965-48383F36-E2ED-4739-BE7E-18893EE89311Q35146806-56B60DF9-586D-4E1E-9D23-9FB8BB5CA35AQ35533948-B7256A3A-4B31-48DF-971A-D1897305C278Q35568496-34D9C663-18C7-41A5-9B2E-4813536E4609Q35621233-B170F136-5E56-46F3-8D38-382BB3F00569Q35666632-B69BC3CE-EC96-4E49-B2ED-9A2A86FEA968Q35847422-5CD7211E-7D71-4941-890E-7B6407D2C0B6Q35848490-ED1F7A25-2BA0-4773-9FC3-63AF6E89AE4CQ36059960-04AF6DB2-8AAD-46BD-9C2C-9B7BFB6DBAE9Q36092690-EEC1B35C-411E-44BB-B38B-3D600C1BCA68Q36199866-BA000627-4D67-459B-B292-2D35FDF37BE8Q36247683-6166D668-9B3E-4121-B35A-E6A7649B83DEQ36253827-8F5760E4-7066-48FC-B713-8948466819E7Q36298955-CAD89FE1-CE9A-42D9-95D6-385D20BF478C
P2860
A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A type I interferon signature ...... ron-beta in multiple sclerosis
@ast
A type I interferon signature ...... ron-beta in multiple sclerosis
@en
A type I interferon signature ...... ron-beta in multiple sclerosis
@nl
type
label
A type I interferon signature ...... ron-beta in multiple sclerosis
@ast
A type I interferon signature ...... ron-beta in multiple sclerosis
@en
A type I interferon signature ...... ron-beta in multiple sclerosis
@nl
altLabel
A type I interferon signature ...... rferon- in multiple sclerosis
@en
prefLabel
A type I interferon signature ...... ron-beta in multiple sclerosis
@ast
A type I interferon signature ...... ron-beta in multiple sclerosis
@en
A type I interferon signature ...... ron-beta in multiple sclerosis
@nl
P2093
P2860
P50
P356
P1433
P1476
A type I interferon signature ...... ron-beta in multiple sclerosis
@en
P2093
E Caballero
F Deisenhammer
M Camiña-Tato
M Comabella
M Fernández
M T Tortola
P2860
P304
P356
10.1093/BRAIN/AWP228
P407
P577
2009-12-01T00:00:00Z